MENLO PARK, CA – 16 June 2020 – Today, Levitas Bio has announced the commercial release of its flagship product – LeviCell – introducing a disruptive new method for cell researchers and scientists to sort live cells without the use of markers or antibodies.
For the first time, researchers now have access to all high-value primary samples regardless of starting cell number or viability. Leveraging proprietary levitation technology developed at Stanford University, the LeviCell delivers simple, label-free cell separation in a fast, reliable, and very gentle solution to sort fully viable cell populations.
“For many researchers, this means that they can now explore the beneficial uses of previously inaccessible, high-value primary samples and sensitive cell types regardless of the starting cell number or viability,” says Martin Pieprzyk, Chief Executive Officer at Levitas Bio.
The technology was first demonstrated by researchers at Stanford and Harvard Universities. Levitas technology allows scientists to identify, isolate, quantify, collect, and test cells based on their intrinsic physical characteristics and profiles. The approach has been validated for sorting fully viable live populations from highly heterogeneous and traditionally very difficult to work with sample types, such as tumor biopsies, tissue, and needle aspirates as well as very sensitive cell types as pancreatic cells, adipocytes, and macrophages.
“Up until today, researchers have had to make several compromises in their research methods during sample prep and cell manipulation. You either stain and damage cells, you compromise yield, or you have lower levels of accuracy. With Levitas’ LeviCell, researchers no longer need to make that compromise and can speed up their workflow to really separate cells in minutes instead of hours,” says Geoff Facer, VP of Engineering at Levitas. “We are thrilled about the opportunities this technology will open up for oncology, bacteriology, and immunology research.”
Learn More at Levitasbio.com
Read more about Levitas Bio here.